공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

전이성 신세포암 : 세계 임상시험 리뷰

Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2017

리서치사 GlobalData
발행일 2017년 12월 상품 코드 299728
페이지 정보 영문 628 Pages
가격
US $ 2,500 ₩ 2,818,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,636,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,500 ₩ 8,454,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


전이성 신세포암 : 세계 임상시험 리뷰 Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2017
발행일 : 2017년 12월 페이지 정보 : 영문 628 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

전이성 신세포암(Metastatic Renal Cell Carcinoma) 치료제에 관한 임상시험의 최신 동향에 대해 분석했으며, 주요 7개국(G7) 및 신흥 7개국(E7)의 임상시험 건수, 피험자수, 유망한 스폰서, 임상시험에 참여하고 있는 주요 기업과 기관, 유망한 약제 등의 정보를 정리하여 전해드립니다.

본 보고서의 개요

각 지역의 임상시험 상황

  • 각국의 임상시험 건수와 평균 피험자수
    • 아시아태평양 지역 주요 5개국의 임상시험 건수
    • 유럽 주요 5개국의 임상시험 건수
    • 북미 주요 국가의 임상시험 건수
    • 중동 및 아프리카 주요 5개국의 임상시험 건수
    • 중남미 주요 5개국의 임상시험 건수

G7 국가에서의 임상시험 건수 : 암 치료제 임상시험에서 전이성 신세포암 임상시험 비율

G7 국가에서의 단계별 임상시험 건수

G7 국가에서의 임상시험 건수 : 진척 상황별

E7 국가에서의 임상시험 건수 : 암 치료제 임상시험에서 전이성 신세포암 임상시험 비율

E7 국가에서의 단계별 임상시험 건수

E7 국가에서의 임상시험 건수 : 진척 상황별

단계별 임상시험 건수

  • 진행중인 임상시험 : 단계별

진척 상황별 임상시험 건수

임상시험 목표 달성 상황

일정기간에 채용된 피험자

스폰서 종류별 임상시험 건수

유망한 스폰서

전이성 신세포암 치료제 임상시험에 참여하고 있는 주요 기업

유망한 약제

최신 임상시험 뉴스

임상시험 프로파일 개요

부록

LSH 16.09.30

GlobalData's clinical trial report, "Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2017" provides an overview of Metastatic Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 3
  • List of Figures 4
  • Report Guidance 5
  • GlobalData Clinical Trials Report Coverage 6
  • Clinical Trials by Region 7
  • Clinical Trials and Average Enrollment by Country 8
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
  • Top Five Countries Contributing to Clinical Trials in Europe 11
  • Top Countries Contributing to Clinical Trials in North America 12
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
  • Top Five Countries Contributing to Clinical Trials in Central and South America 14
  • Clinical Trials by G7 Countries: Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials 15
  • Clinical Trials by Phase in G7 Countries 16
  • Clinical Trials in G7 Countries by Trial Status 17
  • Clinical Trials by E7 Countries: Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials 18
  • Clinical Trials by Phase in E7 Countries 19
  • Clinical Trials in E7 Countries by Trial Status 20
  • Clinical Trials by Phase 21
  • In Progress Trials by Phase 22
  • Clinical Trials by Trial Status 23
  • Clinical Trials by End Point Status 24
  • Subjects Recruited Over a Period of Time 25
  • Clinical Trials by Sponsor Type 26
  • Prominent Sponsors 27
  • Top Companies Participating in Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials 28
  • Prominent Drugs 29
  • Latest Clinical Trials News on Metastatic Renal Cell Carcinoma 30
  • Dec 08, 2017: ARMO BioSciences Presents Efficacy Data from its Phase 1b Trial in Patients with Metastatic Renal Cell Carcinoma at ESMO Immuno-Oncology Congress 2017 30
  • Nov 28, 2017: European Medicines Agency Validates Bristol-Myers Squibb's Type II Variation Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma 30
  • Nov 11, 2017: Argos Therapeutics Provides Update on Immunology Data from the Phase 3 ADAPT Trial Presented at the SITC 2017 Annual Meeting 31
  • Nov 07, 2017: Opdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 32
  • Clinical Trial Profile Snapshots 33

Appendix 625

  • Abbreviations 625
  • Definitions 625
  • Research Methodology 626
  • Secondary Research 626
  • About GlobalData 627
  • Contact Us 627
  • Disclaimer 627
  • Source 628

List of Tables

List of Tables

  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Region, 2017* 7
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 9
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 10
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 11
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 12
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 13
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 14
  • Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, G7 Countries (%), 2017* 15
  • Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 16
  • Metastatic Renal Cell Carcinoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 17
  • Proportion of Metastatic Renal Cell Carcinoma to Oncology Clinical Trials, E7 Countries (%), 2017* 18
  • Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 19
  • Metastatic Renal Cell Carcinoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Phase, 2017* 21
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 22
  • Metastatic Renal Cell Carcinoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 23
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 24
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 25
  • Metastatic Renal Cell Carcinoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 26
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 27
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 28
  • Metastatic Renal Cell Carcinoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 29
Back to Top
전화 문의
F A Q